Safety of hydroxychloroquine for treatment or prevention of SARS-CoV-2 infection: A rapid systematic review and meta-analysis of randomized clinical trials.


Journal

Immunity, inflammation and disease
ISSN: 2050-4527
Titre abrégé: Immun Inflamm Dis
Pays: England
ID NLM: 101635460

Informations de publication

Date de publication:
03 2021
Historique:
received: 24 09 2020
revised: 26 10 2020
accepted: 28 10 2020
pubmed: 28 11 2020
medline: 12 2 2021
entrez: 27 11 2020
Statut: ppublish

Résumé

Hydroxycloroquine (HCQ) has been extensively studied for treatment and prevention of coronavirus diseases 2019 (COVID-19) from the start of the pandemic. Conflicting evidence about its usefulness has begun to accrue. In the face of controversial results about clinical efficacy of HCQ, we performed a rapid systematic review to assess its safety in the framework of COVID-19 randomized clinical trials. Five studies investigating 2291 subjects were included. The use of HCQ was associated with higher risk of adverse event compared with placebo or standard of care: odds ratio 4.57, 95% confidence interval 2.14-9.45. Safety profile of HCQ appears to be unsatisfactory when used to treat or prevent COVID-19, especially in the light of unproved clinical benefit.

Identifiants

pubmed: 33244901
doi: 10.1002/iid3.374
pmc: PMC7753686
doi:

Substances chimiques

Hydroxychloroquine 4QWG6N8QKH

Types de publication

Journal Article Meta-Analysis Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

31-36

Informations de copyright

© 2020 The Authors. Immunity, Inflammation and Disease published by John Wiley & Sons Ltd.

Références

PLoS Med. 2009 Jul 21;6(7):e1000097
pubmed: 19621072
Ann Intern Med. 2020 Oct 20;173(8):623-631
pubmed: 32673060
N Engl J Med. 2020 Aug 6;383(6):517-525
pubmed: 32492293
Eur J Clin Pharmacol. 2021 Jan;77(1):13-24
pubmed: 32780229
Int J Antimicrob Agents. 2020 Jul;56(1):106063
pubmed: 32674928
Immun Inflamm Dis. 2021 Mar;9(1):31-36
pubmed: 33244901
Clin Microbiol Infect. 2021 Jan;27(1):19-27
pubmed: 32860962
BMJ Open. 2016 Jul 12;6(7):e010247
pubmed: 27406637
N Engl J Med. 2020 Nov 19;383(21):2041-2052
pubmed: 32706953
Clin Microbiol Infect. 2020 Sep;26(9):1276-1277
pubmed: 32422406
Clin Microbiol Infect. 2020 Aug;26(8):979-987
pubmed: 32470568
BMJ. 2020 May 14;369:m1849
pubmed: 32409561
BMJ. 2019 Aug 28;366:l4898
pubmed: 31462531
Clin Infect Dis. 2021 Dec 6;73(11):e4073-e4081
pubmed: 32674126
BMJ. 2020 Jul 30;370:m2980
pubmed: 32732190

Auteurs

Alberto Enrico Maraolo (AE)

First Division of Infectious Diseases, Cotugno Hospital, Naples, Italy.

Adriano Grossi (A)

Section of Hygiene, University Department of Life Sciences and Public Health, Università Cattolica del Sacro Cuore, Roma, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH